GlassScriptPhysician profile
Anna D Nowobilska
NPI 1255373866
$8,041.02
in general payments reported to CMS, 2019-2025
43 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $661 · 2021: $1,407 · 2022: $1,590 · 2023: $1,073 · 2024: $1,285 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,506.88 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,231.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $973.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $539.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $352.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $332.83 | 2019-2024 | |
| Glaxosmithkline, LLC. | $308.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $288.35 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $269.57 | 2019-2024 | Eliquis |
| Exact Sciences Corporation | $228.05 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.16 | 2022-2023 | |
| Allergan, INC. | $171.56 | 2019 | |
| Amgen INC. | $167.23 | 2019-2024 | Repatha |
| Preventric Diagnostics, INC. | $157.16 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Nowobilska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.